Cargando…
Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma
BACKGROUND: Although sorafenib is accepted as the standard of care in advanced hepatocellular carcinoma (HCC), its therapeutic benefit is marginal. Here, we aimed to compare the efficacy and safety of sorafenib monotherapy (S-M) and sorafenib-based loco-regional treatments (S-LRTs) in advanced HCC....
Autores principales: | Lee, Sangheun, Kim, Beom Kyung, Kim, Seung Up, Park, Yehyun, Chang, Sooyun, Park, Jun Yong, Kim, Do Young, Ahn, Sang Hoon, Chon, Chae Yoon, Han, Kwang-Hyub |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3796498/ https://www.ncbi.nlm.nih.gov/pubmed/24155932 http://dx.doi.org/10.1371/journal.pone.0077240 |
Ejemplares similares
-
Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib
por: Lee, Sangheun, et al.
Publicado: (2015) -
Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma
por: Yoo, Eun Jin, et al.
Publicado: (2013) -
Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation
por: Lee, Hye Won, et al.
Publicado: (2017) -
Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
por: Kim, Jina, et al.
Publicado: (2022) -
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort
por: Ahn, Sung Soo, et al.
Publicado: (2014)